No Data
Calendar of U.S. Earnings Expected in the Week Ahead
Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More
Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?
Express News | HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target
Anavex Life Sciences: Buy Rating Driven by Promising Blarcamesine Developments and Market Expansion
Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
